3 news items
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
1
0
0
The 12-month price targets assessed
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
to assess and enhance HBV patients' intrinsic immunity, targeting therapies to those most likely to respond, while sparing others from poorly
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
VIR
15 Mar 24
three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below
- Prev
- 1
- Next